Regulation of metalloproteinases and NF-κB activation in rabbit synovial fibroblasts via E prostaglandins and Erk: Contrasting effects of nabumetone and 6MNA

British Journal of Pharmacology

Volumn 142, Issue 6, 2004, Pages 973-982

  Pillinger, Michael H ^a,b,c   Dinsell, Victoria ^a,b,c   Apsel, Beth ^a,b,c   Tolani, Sonia N ^a,b,c   Marjanovic, Nada ^a,c   Chan, Edwin S L ^a   Gomez, Paul ^a,b   Clancy, Robert ^a,b   Chang, Lih Fan ^a,c   Abramson, Steven B ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

6MNA; Cyclooxygenase; Erk; MAP kinase; Matrix metalloproteinase; Nabumetone; NF B; Prostaglandin; Synoviocyte

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; COLLAGENASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NABUMETONE; NITRIC OXIDE; PROSTAGLANDIN E1; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UO 126;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME RELEASE; FATTY ACID METABOLISM; FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RABBIT; SYNOVIOCYTE;

ALPROSTADIL; ANALYSIS OF VARIANCE; ANIMALS; BUTADIENES; BUTANONES; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; IMIDAZOLES; INTERLEUKIN-1; MATRIX METALLOPROTEINASE 1; METALLOENDOPEPTIDASES; NAPHTHALENEACETIC ACIDS; NF-KAPPA B; NITRIC OXIDE; NITRILES; PHOSPHORYLATION; PROSTAGLANDINS E; PYRIDINES; RABBITS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3843092892     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705864     Document Type: Article

References (51)

1. ALPERT, D., SCHWENGER, P., HAN, J. & VILCEK, J. (1999). Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IkappaB phosphorylation and NF-kappaB activation. J. Biol. Chem., 274, 22176-22183.
2. ALPERT, D. & VILCEK, J. (2000). Inhibition of IkappaB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells. J. Biol. Chem., 275, 10925-10929.
3. BANDEIRA-MELO, C., SERRA, M.F., DIAZ. B.L., CORDEIRO, R.S., SILVA, P.M., LENZI, H.L., BAKHLE, Y.S., SERHAN, C.N. & MARTINS, M.A. (2000). Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol., 164, 1029-1036.
4. BASSON, M.D., PANZINI, L. & PALMER, R.H. (2001). Effect of nabumetone and aspirin on colonie mucosal bleeding time. Aliment. Pharmacol. Ther., 15, 539-542.
5. BIRKENKAMP, K.U., TUYT, L.M., LUMMEN, C., WIERENGA, A.T., KRUIJER, W. & VELLENGA, E. (2000). The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br. J. Pharmacol., 131, 99-107.
6. BLOWER, P.R. (1992). The unique pharmacologic profile of nabumetone. J. Rheumatol., 19 (Suppl 36), 13-19.
7. CLANCY, R.M., GOMEZ, P. & ABRAMSON, S.B. (2002). Intracellular peroxynitrite formation promotes NK-κB translocation and apoptosis in cytokine-activated chondrocytes. Arthritis Rheum., 46, S594 (abstract).
8. CUENDA, A., ROUSE, J., DOZA, Y.N., MEIER, R., COHEN, P., GALLAGHER, T.F., YOUNG, P.R. & LEE, J.C. (1995). SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 364, 229-233.
9. DAVIES, N.M. (1997). Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin. Pharmacokinet., 33, 404-416.
10. DAYER, J.M., KRANE, S.M., RUSSELL, R.G. & ROBINSON, D.R. (1976). Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc. Natl. Acad. Sci. U.S.A., 73, 945-949.
11. DIBATTISTA, J.A., MARTEL-PELLETIER, J., FUJIMOTO, N., OBATA, K., ZAFARULLAH, M. & PELLETIER, J.P. (1994). Prostaglandins E2 and El inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway. Lab. Invest., 71, 270-278.
12. FAVATA, M.F., HORIUCHI, K.Y., MANOS, E.J., DAULERIO, A.J., STRADLEY, D.A., FEESER, W.S., VAN DYK, D.E., PITTS, W.J., EARL, R.A., HOBBS, F., COPELAND, R.A., MAGOLDA, R.L., SCHERLE, P.A. & TRZASKOS, J.M. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273, 18623-18632.
13. FIRESTEIN, G.S. (1998). Rheumatoid synovitis and pannus. In: Rheumatology, ed. Maini, R.N., Zvaifler, N.J., Klippel, J.H., Dieppe, P.A. pp. 13.1-13.24. London: Mosby.
14. GARCIA-GARCIA, E., SANCHEZ-MEJORADA, G. & ROSALES, C. (2001). Phosphatidylinositol 3-kinase and ERK are required for NF-kappaB activation but not for phagocytosis. J. Leukoc. Biol., 70, 649-658.
15. GEORGESCU, H.I., MENDELOW, D. & EVANS, C.H. (1988). HIG-82: an established cell line from rabbit periarticular soft tissue, which retains the 'activatable' phenotype. In vitro Cell. Dev. Biol., 24, 1015-1022.
16. GHOSH, S., MAY, M.J. & KOPP, E.B. (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 16, 225-260.
17. GU, Z., KAUL, M., YAN, B., KRIDEL, S.J., CUI, J., STRONGIN, A., SMITH, J.W., LIDDINGTON, R.C. & LIPTON, S.A. (2002). S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science, 297, 1186-1190.
18. HADDOCK, R.E., JEFFERY, D.J., LLOYD, J.A. & THAWLEY, A.R. (1984). Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica, 14, 327-337.
19. HE, W., PELLETIER, J.P., MARTEL-PELLETIER, J., LAUFER, S. & DI BATTISTA, J.A. (2002). Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J. Rheumatol., 29, 546-553.
20. HELFGOTT, S.M. (1994). Nabumetone: a clinical appraisal. Semin. Arthritis Rheum., 23, 341-346.
21. HYNECK, M.L. (1992). An overview of the clinical pharmacokinetics of nabumetone. J. Rheumatol., 19 (Suppl 36), 20-24.
22. ISHIWATA, Y., OKAMOTO, M., YOKOCHI, S., HASHIMOTO, H., NAKAMURA, T., MIYACHI, A., NAITO, Y. & YOSHIKAWA, T. (2003). Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions. J. Pharm. Pharmacol., 55, 229-237.
23. JOVANOVIC, D.V., MINEAU, F., NOTOYA, K., REBOUL, P., MARTEL-PELLETIER, J. & PELLETIER, J.P. (2002). Nitric oxide induced cell death in human osteoarthritic synoviocytes is mediated by tyrosine kinase activation and hydrogen peroxide and/or superoxide formation. J. Rheumatol., 29, 2165-2175.
24. KOPP, E. & GHOSH, S. (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 265, 956-959.
25. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
26. LIACINI, A., SYLVESTER, J., LI, W.Q. & ZAFARULLAH, M. (2002). Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol., 21, 251-262.
27. MELARANGE, R., GENTRY, C., O'CONNELL, C., BLOWER, P.R., NEIL, C., KELVIN, A.S. & TOSELAND, C.D. (1992). Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin. Agents Actions, 35, Spec No C82-C83.
28. MENDES, A.F., CARAMONA, M.M., CARVALHO, A.P. & LOPES, M.C. (2002). Role of mitogen-activated protein kinases and tyrosine kinases on IL-1-induced NF-kappaB activation and iNOS expression in bovine articular chondrocytes. Nitric Oxide, 6, 35-44.
29. MENGSHOL, J.A., VINCENTI, M.P., COON, C.I., BARCHOWSKY, A. & BRINCKERHOFF, C.E. (2000). Interleukin-1 induction of collage-nase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum., 43, 801-811.
30. MIEHLKE, R.K., SCHNEIDER, S., SORGEL, F., MUTH, P., HENSCHKE, F., GIERSCH, K.H. & MUNZEL, P. (1990). Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery. Drugs, 40 (Suppl 5), 57-61.
31. MORGAN JR, G.J., KAINE, J., DELAPP, R. & PALMER, R. (2001). Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. J. Clin. Gastroenterol., 32, 310-314.
32. PATEL, R., ATTUR, M.G., DAVE, M.N., KUMAR, S., LEE, J.C., ABRAMSON, S.B. & AMIN, A.R. (1999). Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS. Inflamm. Res., 48, 337-343.
33. PILLINGER, M.H., CAPODICI, C., ROSENTHAL, P., KHETERPAL, N., HANFT, S., PHILIPS, M.R. & WEISSMANN, G. (1998). Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. Proc. Natl. Acad. Sci. U.S.A., 95, 14540-14545.
34. PILLINGER, M.H., PHILIPS, M.R., FEOKTISTOV, A. & WEISSMANN, G. (1995). Crosstalk in signal transduction via EP receptors: prostaglandin E1 inhibits chemoattractant-induced mitogen-activated protein kinase activity in human neutrophils. Adv. Prostagland. Thromboxane Leukotr. Res., 23, 311-316.
35. PILLINGER, M.H., ROSENTHAL, P.B., TOLANI, S.N., APSEL, B., DINSELL, V., GREENBERG, J., CHAN, E.S., GOMEZ, P.F. & ABRAMSON, S.B. (2003). Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signalregulated kinase activation. J. Immunol., 171, 6080-6089.
36. PILLINGER, M.H., VOLKER, C., STOCK, J.B., WEISSMANN, G. & PHILIPS, M.R. (1994). Characterization of a plasma membrane-associated prenylcysteine-directed alpha carboxyl methyltransferase in human neutrophils. J. Biol. Chem., 269, 1486-1492.
37. ROSSETTI, R.G., BRATHWAITE, K. & ZURIER, R.B. (1994). Suppression of acute inflammation with liposome associated prostaglandin E1. Prostaglandins, 48, 187-195.
38. SAKAI, T., KAMBE, F., MITSUYAMA, H., ISHIGURO, N., KUROKOUCHI, K., TAKIGAWA, M., IWATA, H. & SEO, H. (2001). Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors. J. Bone Miner. Res., 16, 1272-1280.
39. SALVATORI, R., GUIDON JR, P.T., RAPUANO, B.E. & BOCKMAN, R.S. (1992). Prostaglandin El inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinology, 131, 21-28.
40. SASAKI, K., HATTORI, T., FUJISAWA, T., TAKAHASHI, K., INOUE, H. & TAKIGAWA, M. (1998). Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J. Biochem. (Tokyo), 123, 431-439.
41. SCHWENGER, P., SKOLNIK, E.Y. & VILCEK, J. (1996). Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J. Biol. Chem., 271, 8089-8094.
42. SUZUKI, K., RAPUANO, B.E. & BOCKMAN, R.S. (1997). Role of protein kinase A in collagenase-1 gene regulation by prostaglandin E1: studies in a rabbit synoviocyte cell line, HIG-82. J. Bone Miner. Res., 12, 561-567.
43. TAMURA, T., NAKANISHI, T., KIMURA, Y., HATTORI, T., SASAKI, K., NORIMATSU, H., TAKAHASHI, K. & TAKIGAWA, M. (1996). Nitric oxide mediates interleukin-1 -induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinology, 137, 3729-3737.
44. TORRE, D., SAMPIETRO, C. & MAGGIOLO, F. (1987). Blood and tissue fluid levels of a new non-steroidal anti-inflammatory preparation of nabumetone. J. Int. Med. Res., 15, 368-373.
45. VINCENTI, M.P. & BRINCKERHOFF, C.E. (2002). Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res., 4, 157-164.
46. WARNER, T.D., GIULIANO, F., VOJNOVIC, I., BUKASA, A., MITCHELL, J.A. & VANE, J.R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Nad. Acad. Sci. U.S.A., 96, 7563-7568.
47. YAMANISHI, Y. & FIRESTEIN, G.S. (2001). Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum. Dis. Clin. North Am., 27, 355-371.
48. ZARAGOZA, C., SORIA, E., LOPEZ, E., BROWNING, D., BALBIN, M., LOPEZ-OTIN, C. & LAMAS, S. (2002). Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cGMP- dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial cells. Mol. Pharmacol., 62, 927-935.
49. ZHANG, P., WANG, Y.Z., KAGAN, E. & BONNER, J.C. (2000). Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J. Biol. Chem., 275, 22479-22486.
50. ZURIER, R.B., DAMJANOV, I., SAYADOFF, D.M. & ROTHFIELD, N.F. (1977). Prostaglandin E1 treatment of NZB/NZW F1 hybrid mice. II. Prevention of glomerulonephritis. Arthritis Rheum., 20, 1449-1456.
51. ZURIER, R.B. & QUAGLIATA, F. (1971). Effect of prostaglandin E 1 on adjuvant arthritis. Nature, 234, 304-305.